San Antonio's CytoBioscience closing in on acquisition deal
CytoBioscience CEO James Garvin says a deal for BioDtech could be finalized in a matter of weeks. If finalized, CytoBioscience will get access to new revenue streams and greater collaborative opportunities.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.